Eng. Hazem El-Ashmouny, Governor of Sharkia, inaugurated the new expansion works of one of the leading companies in the production and manufacturing of veterinary vaccines in the Middle East and North Africa region, with a presence in more than 42 countries around the world, in New Salhia City. The governor expressed his pleasure at participating in the inauguration of the company's third industrial facility, which represents a strong industrial and scientific edifice and represents a strong addition to the veterinary pharmaceutical industry in Egypt. It represents a qualitative leap in the level of distinguished local production that meets international standards. The governor also thanked the company's Board of Directors and all the national hands that contributed to the establishment of this vital project, which represents an exemplary model of partnership between scientific research and industry. He emphasized that the governorate will always remain an attractive environment for investment and production, and is committed providing all means of support to serious investors, within the framework of the directives of the wise political leadership, which places the development of national industry at the forefront of its priorities. The opening ceremony included an inspection tour of the company by the governor and his entourage to learn about the scope of the new expansions. Dr. Magdy El-Sayed, Chairman of the Board of Directors, gave a presentation on the company's origins and its investments in the Egyptian market, which, after the expansions, amounted to approximately EGP 5 billion. He noted that the factory was established in 2006 through an Egyptian-Arab-American partnership when Egypt faced epidemic challenges in the poultry and livestock sectors, including the spread of avian influenza and foot-and-mouth disease. The factory employs 820 highly skilled employees and researchers, specializing in the production and manufacture of world-class vaccines for better animal health. The Chairman of the Board of Directors added that the new building is equipped with two advanced automated production lines designed to enhance manufacturing capacity by more than 4 billion additional doses according to the highest standards of quality and efficiency. This will allow the company to meet the growing demand for vaccines for global export, amounting to more than one billion Egyptian pounds in 2025, and more than 5 billion Egyptian pounds by 2029, with a share of up to 25% in the local market by 2026. This is in addition to the expansion of the production line for foot-and-mouth disease and lumpy skin disease vaccines with a capacity of up to 50 million doses annually. He pointed out that the expansions will enable the company to reach a production capacity of more than 12 billion doses of poultry vaccines and more than 120 million doses of ruminant vaccines in the coming period.